REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat

导出原文传递

翻译打印收藏纠错

作者： Benza, Raymond L. ^[1] ; Farber, Harrison W. ^[2] ; Frost, Adaani ^[3] ; Gruenig, Ekkehard ^[4] ; Hoeper, Marius M. ^[5] ; Busse, Dennis ^[6] ; Meier, Christian ^[7] ; Nikkho, Sylvia ^[8] ; Ghofrani, Hossein-Ardeschir ^[9]

作者单位： Houston Methodist Hosp, Houston, TX USA ^[1] Hannover Med Sch, German Ctr Lung Res DZL, Clin Resp Med, Hannover, Germany ^[2] Bayer AG, Global Med Affairs, Berlin, Germany ^[3] Bayer AG, Global Clin Dev, Berlin, Germany ^[4] Chrestos Concept GmbH & Co KG, Essen, Germany ^[5] Allegheny Gen Hosp, Cardiovasc Inst, 320 East North Ave, Pittsburgh, PA 15212 USA ^[6] Univ Giessen, Giessen, Germany ^[7] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA ^[8] Univ Hosp Heidelberg, Ctr Pulm Hypertens, Thorax Clin, Heidelberg, Germany ^[9]

关键词 chronic thromboembolic pulmonary hypertension clinical trial pulmonary riociguat soluble guanylate cyclase stimulator

发布时间 2020-02-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交